- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Conshohocken Today
By the People, for the People
Madrigal Pharmaceuticals Grants Inducement Awards to New Employees
The biopharmaceutical company awarded restricted stock units to 20 new non-executive hires.
Apr. 8, 2026 at 6:04am
Got story updates? Submit your updates here. ›
Madrigal Pharmaceuticals' latest inducement awards underscore its commitment to expanding its workforce and advancing its pipeline of novel MASH treatments.Conshohocken TodayMadrigal Pharmaceuticals, a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), announced that it granted equity awards on April 1, 2026 to 20 new non-executive employees as inducement awards under the terms of the company's 2025 Inducement Plan. The new employees received a total of 8,079 time-based restricted stock units that vest over four years.
Why it matters
Inducement awards are a common practice for public companies to attract and retain top talent, especially in the competitive biopharmaceutical industry. These grants demonstrate Madrigal's commitment to expanding its workforce as it continues to advance its lead MASH drug candidate, Rezdiffra, through late-stage clinical trials.
The details
The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), which allows public companies to issue inducement awards to new employees without shareholder approval. All of the restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to the employees' continued employment.
- Madrigal granted the inducement awards on April 1, 2026.
- The restricted stock units vest over a four-year period, with 25% vesting annually.
The players
Madrigal Pharmaceuticals, Inc.
A biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
Rezdiffra (resmetirom)
Madrigal's lead medication, a once-daily, oral, liver-directed THR-β agonist designed to treat MASH.
What’s next
Madrigal is currently conducting a Phase 3 outcomes trial evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).
The takeaway
Madrigal's inducement awards demonstrate the company's commitment to expanding its workforce and advancing its lead MASH drug candidate, Rezdiffra, as it continues to navigate the competitive biopharmaceutical landscape.
